Fmoc-based solid-phase peptide synthesis for oral tablet, capsule, and granule APIs uses pharma-grade HATU (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate, CAS 148893-10-1) in the coupling step. Pharma-grade HATU is released with HPLC purity ≥99.0% and water content ≤0.5% by Karl Fischer titration. HATU itself is not an active pharmaceutical ingredient in the finished oral dosage form; it is consumed during activation of the incoming Fmoc-amino acid and is removed by resin washing, precipitation, and preparative HPLC. A PTFE-bottom glass peptide reactor is charged with 2-chlorotrityl chloride resin at 0.8–1.2 mmol/g substitution. Fmoc removal uses 20% piperidine in DMF. The coupling cocktail is prepared from 1.1 eq Fmoc-amino acid, 1.1 eq HATU, and 2.0 eq DIPEA in DMF. Pre-activation is held at 20–25 °C for 2–5 min to form the 7-aza-HOAt active ester while limiting hydrolysis. The activated solution is recirculated through the resin bed for 30–60 min under nitrogen. After TFA cleavage and ether precipitation, the crude peptide is purified by preparative HPLC. Residual DMF, NMP, and acetonitrile are controlled per ICH Q3C Table 2 with PDE values of 8.8 mg/day, 5.3 mg/day, and 4.1 mg/day respectively. HPLC purity is assessed per USP <621> with UV detection at 214–220 nm; LC-MS is used to monitor tetramethylurea and HOAt process-related impurities. The terminal output is a linear peptide API suitable for tablet compression, capsule filling, or granule formulation after lyophilization or spray drying.

What Limits Solution-Phase Fragment Condensation for Injectable Peptide APIs?

Solution-phase fragment condensation for 30–40 amino acid injectable peptide APIs is used to reduce SPPS waste and improve overall yield. HATU activation is carried out in DMF or DMF/DCM mixtures at -10 to 5 °C in a glass-lined jacketed reactor. The C-terminal fragment carboxylic acid is charged at 1.0 eq, HATU at 1.05–1.2 eq, and 2,4,6-trimethylpyridine or N-methylmorpholine at 1.5–2.0 eq. Water content is maintained below 0.1% by Karl Fischer titration per USP <921> method Ic because residual moisture hydrolyzes the uronium reagent and lowers coupling efficiency. Pre-activation time is limited to 2–3 min before addition of the N-terminal fragment to suppress epimerization of C-terminal histidine, cysteine, and phenylalanine. The final API is converted to acetate or hydrochloride salt by ion-exchange chromatography, then lyophilized. Injectable final formulations are released under USP <790> for visible particulate and USP <85> for bacterial endotoxin; endotoxin limits are calculated from dose, body weight, and route per USP <85>.

Temperature excursions above 10 °C during activation can increase D-isomer content in fragment condensations. 2,4,6-Trimethylpyridine reduces base-catalysed enolization compared with DIPEA but slows activation; therefore, preactivation is conducted in a separate vessel with overhead agitation and a nitrogen overlay. Batch-to-batch variance in tetramethylurea removal is observed when DMF quality is not controlled; freshly opened pharma-grade DMF with KF value below 0.05% is used. The process is operated under ICH Q7 for API GMP, with equipment maintenance and cleaning per 21 CFR 211.65. Published data for specific D-isomer limits in solution fragment couplings using HATU is limited; chiral HPLC method validation per process must be performed.

When continuous manufacturing replaces batch SPPS for oral peptide APIs, the HATU coupling step is transferred to a silicon carbide plate reactor with peristaltic pumps and a back-pressure regulator at 2–5 bar. Stock solutions of Fmoc-amino acid (0.3–0.5 M), HATU (0.3–0.5 M), and DIPEA (0.6–1.0 M) in anhydrous DMF are prepared in sealed stainless-steel vessels and degassed before use. Residence time is held at 2–10 min at 20–40 °C. In-line FTIR tracks active ester formation, and the activated stream is immediately transferred to the resin column to avoid hydrolysis of the transient 7-aza-HOAt ester. This configuration limits thermal degradation of HATU by minimizing hold time at activation temperature. Cleavage and workup remain batch operations in hybrid layouts. Regulatory submissions for continuous coupling reference ICH Q13 for continuous manufacturing and ICH Q11 for starting material definition. The terminal API is a linear oral peptide for granule or tablet dosage after lyophilization.

One operational boundary is DMF viscosity at concentrations above 0.5 M, which can cause peristaltic pump cavitation unless inlet lines are held at 25–30 °C. HATU stock solutions in DMF degrade measurably after 12–24 h at room temperature; a single-campaign batch is prepared fresh per shift. Residual water in DMF must remain below 0.05% by KF. Published data for specific yield improvements in continuous HATU-mediated coupling relative to batch SPPS is limited; process-specific studies are required for each peptide sequence because coupling rates vary with steric hindrance and side-chain protection.

Residual HATU-Derived Tetramethylurea and Guanidinylation Byproduct Control in Preparative HPLC Purification

Crude peptide after TFA cleavage contains tetramethylurea, HOAt, and occasionally tetramethylguanidinylated peptides as process-related impurities. Preparative HPLC on C18 10 µm 100 Å media with a 15 cm ID column and acetonitrile/0.1% TFA gradient separates tetramethylurea from the target peptide. LC-MS detection in positive ion mode monitors tetramethylurea at m/z 117.16. Fractions are pooled when the target peptide purity exceeds the ICH Q3A reporting threshold of 0.05% for any single impurity at a maximum daily dose ≤2 g/day; for doses above 2 g/day, the reporting threshold falls to 0.03%. The purified peptide is converted to the acetate salt by ion exchange and lyophilized. This process is applied to oral capsule and granule peptide APIs where residual tetramethylurea must be below the reporting threshold before release.

Guanidinylation occurs when HATU is present in excess or free amino groups are present during activation. The tetramethylguanidinium adduct at Lys Nε is detectable by peptide mapping with trypsin and LC-MS/MS. To avoid this, HATU excess is kept at ≤1.05 eq for fragment condensations and preactivation is completed in a separate vessel before contact with the amino component. If guanidinylation is detected above the identification threshold of 0.10% at a daily dose ≤2 g/day, the batch is rejected or reprocessed by preparative HPLC. This is a high-risk failure mode in synthesizing long peptides with multiple Lys residues, especially when using excess HATU to force difficult couplings.

Under high-dilution macrolactamization conditions, cyclic peptide APIs for injectable microsphere and depot formulations are prepared with a 1.2 eq HATU charge in DMF at 0–5 °C. The linear precursor concentration is maintained at 1 mM in a 50 L glass reactor, and the activated acid solution is added by syringe pump over 4–8 h to suppress intermolecular oligomerization. DIPEA is split into two portions: 50% in the activation vessel and 50% added slowly after the first 30 min to prevent transient overbasification and C-terminal epimerization. After cyclization, the crude product is concentrated, precipitated in methyl tert-butyl ether, and purified by preparative HPLC. Residual metals are controlled per ICH Q3D; residual solvents are controlled per ICH Q3C. Final cyclic peptide API is ion-exchanged to acetate and lyophilized before encapsulation in PLGA microspheres. The finished injectable suspension is tested per USP <788> for subvisible particulate matter and per USP <85> for bacterial endotoxins. HATU-related byproducts are removed during precipitation, HPLC, and lyophilization and are not present in the finished dosage form.

Oligomer-to-monomer ratios are monitored by HPLC at 214 nm over the addition period. If oligomer content increases at the midpoint, the addition rate is decreased or the reactor is diluted further with DMF. Published data for specific cyclic peptide yields with HATU under high dilution is limited; process development batches typically evaluate cyclization efficiency and D-isomer content by chiral HPLC after total hydrolysis. Equipment for this step is a jacketed glass reactor with bottom discharge, nitrogen overlay, and temperature control to ±1 °C.